Specialised clinic to offer regular device monitoring, battery assessment, rhythm evaluation, and expert cardiac electrophysiology consultation
The programme evaluated anselamimab as a first-line add-on to standard plasma cell dyscrasia therapy in patients with advanced cardiac AL amyloidosis
The findings support the continued advancement of EB-003, a first-in-class neuroplastogen designed to selectively target both 5-HT2A and 5-HT1B receptors
Q4FY26 revenue rises 13.6% to Rs. 14,560 crore; quarterly net profit jumps 26.2% to Rs. 2,714 crore driven by India business and Innovative Medicines growth
Eris Lifesciences posts sharp profit surge in FY26 driven by strong diabetes portfolio growth
The company’s revenue stood at Rs. 287.68 crore, reflecting a 4.7 percent increase over Rs. 274.71 crore reported in FY25
Company’s FY26 EBITDA rses 20% to Rs. 8,475 crore; Net profit grows 15% amid strong operational performance
Union Minister Prataprao Jadhav terms hypertension a “silent killer”; experts push for early screening, lifestyle correction and wellness-focused healthcare
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
